APPLICATIONS PUBLISHED 24 APRIL 2002

Published: 1-Nov-2002

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

  • Ophthalmic compsn comprising ketotifen
    Novartis 1198223*

  • Formations of steroid solutions for inhalatory administration
    Chiesi Farmaceutici 1198224*

  • Epothilone compsns
    Novartis 1198225*

  • Mesalazine controlled release oral pharmaceutical compsns
    Cosmo 1198226*

  • Method for producing quickly decomposable solid pharmaceutical preparations
    Bayer 1198227*

  • Release of poorly soluble agents
    Cenes Drug Delivery 1198228*

  • Therapeutic agents
    Knoll 1198229*

  • Use of creatine or creatine compounds for skin preservation
    Avicena 1198230*

  • Bicyclic antagonists selective for the (alpha)V(beta)3 integrin
    American Home Products 1198231*

  • Urea substituted imidazoquinolines
    3M Innovative Properties Company 1198232*

  • Sulphonamide and saulphamide substituted imidazoquinolines
    3M Innovative Properties Company 1198233*

  • Bicyclic aromatic compounds for treating drug addiction
    Knoll 1198234*

  • Method of promoting bone growth with hyaluronic acid and growth factors
    Orquest 1198235*

  • Bone graft substitute compsn
    Wright Medical Technology 1198236*

  • Herbal compsns for itchy or infected skin
    Shah, Eledavi 1198237*

  • Gene encoding NADE, P75NTR-associated cell death executor and uses thereof
    The Trustees of the Columbia University in the City of New York 1198238*

  • Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells
    Cancer Research Ventures 1198239*

  • Tissue regenerating agent
    Max-Delbrueck-Centrum fuer Molekulare Medizin 1198240*

  • Novel proteins
    Genetics Institute 1198241*

  • Autologous thrombin
    Thermogenesis 1198242*

  • Use of CPG as an adjuvant for malaria vaccine
    SmithKline Beecham Biologicals 1198243*

  • Strategy for carbohydrate-based cancer vaccines
    National Research Council Canada 1198244*

  • Use of purified invaplex from gram negative bacteria as a vaccine
    Walter Reed Army Institute of Research 1198245*

  • Method for preventing or attentuating pathangiogenic conditions by using the GBS-toxin (CM101) receptor as a vaccine
    Vanderbilt University 1198246*

  • Compsns and methods related to claudin-7
    Genzyme 1198247*

  • Immunotherapy in HIV infected persons using vaccines after multi-drug treatment
    The Government of the United States of America, represented by the Secretary, Department of Health and Human Services 1198248*

  • PC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
    Lexigen Pharmaceuticals 1198250*

  • Combination of an anti-EP-cam antibody with a chemotherapeutic agent
    Glaxo Group 1198251*

  • Radioenhanced cancer treatment using orally administered camptothecin derivatives
    SuperGen 1198252*

  • Biologically active materials
    ML Laboratories 1198253*

  • Carrier-drug conjugate
    KTB Tumorforschungsgesellschaft 1198254*

  • Identification of compounds that modify transcriptional responses to hypoxia
    Dana-Farber Cancer Institute 1198255*

  • Peptide-lipid conjugates, liposomes and liposomal drug delivery
    The Liposome Corporation 1198256*

  • You may also like